These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 29635268)
21. Delafloxacin (Baxdela) for Skin Infections. Eudaley S Am Fam Physician; 2018 Aug; 98(4):246-247. PubMed ID: 30215969 [No Abstract] [Full Text] [Related]
22. Clarithromycin in patients with coronary artery disease. Med Lett Drugs Ther; 2018 May; 60(1547):89-90. PubMed ID: 29913468 [No Abstract] [Full Text] [Related]
23. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Dawe RS; Ferguson J; Ibbotson S; Lawrence L; Paulson S; Duffy E; Cammarata S Photochem Photobiol Sci; 2018 Jun; 17(6):773-780. PubMed ID: 29721574 [TBL] [Abstract][Full Text] [Related]
24. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration. Lopez Sisniega J; Profant M; Kostrica R; Waskin H Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545 [TBL] [Abstract][Full Text] [Related]
25. [Study on the safety and efficacy of sitafloxacin--results of the use-results survey]. Matsumoto T; Uchino K; Yamaguchi H; Yoshida S; Takahashi M; Kodama H; Hamajima S; Yonemochi R; Fujita S; Takita A; Yamanouchi N; Suzuki T; Shiozawa T; Yamaguchi F Jpn J Antibiot; 2011 Oct; 64(5):319-37. PubMed ID: 22428215 [TBL] [Abstract][Full Text] [Related]
26. Toxic epidermal necrolysis reaction associated with the use of moxifloxacin. Howard-Thompson A; Cartmell B; Suda KJ Int J Antimicrob Agents; 2014 Aug; 44(2):178-9. PubMed ID: 25052867 [No Abstract] [Full Text] [Related]
27. Clinical studies of garenoxacin. Takagi H; Tanaka K; Tsuda H; Kobayashi H Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608 [TBL] [Abstract][Full Text] [Related]
28. In vivo antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic. Li GQ; Bai XG; Li CR; Yang XY; Hu XX; Yuan M; Zhang WX; Lou RH; Guo HY; Jiang JD; You XF J Antimicrob Chemother; 2012 Apr; 67(4):955-61. PubMed ID: 22210757 [TBL] [Abstract][Full Text] [Related]
30. Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. Kang YA; Shim TS; Koh WJ; Lee SH; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Kim KC; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee HK; Heo E; Yim JJ Ann Am Thorac Soc; 2016 Mar; 13(3):364-70. PubMed ID: 26871879 [TBL] [Abstract][Full Text] [Related]
31. Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes. Lode HM Int J Antimicrob Agents; 2014 Jun; 43(6):497-507. PubMed ID: 24787481 [TBL] [Abstract][Full Text] [Related]
33. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Hurst M; Lamb HM; Scott LJ; Figgitt DP Drugs; 2002; 62(14):2127-67. PubMed ID: 12269858 [TBL] [Abstract][Full Text] [Related]
34. Appropriate use of fluoroquinolones in children. Principi N; Esposito S Int J Antimicrob Agents; 2015 Apr; 45(4):341-6. PubMed ID: 25726705 [TBL] [Abstract][Full Text] [Related]
35. [Antibiotics: new and old drugs, rational prescription]. de With K; Stocker H; Borde J; Kern WV Dtsch Med Wochenschr; 2012 Feb; 137(5):186-9. PubMed ID: 22278687 [No Abstract] [Full Text] [Related]
36. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Chou HW; Wang JL; Chang CH; Lee JJ; Shau WY; Lai MS Clin Infect Dis; 2013 Oct; 57(7):971-80. PubMed ID: 23948133 [TBL] [Abstract][Full Text] [Related]
37. Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones. Phillips ST; Nagaro K; Sambol SP; Johnson S; Gerding DN Anaerobe; 2011 Aug; 17(4):166-9. PubMed ID: 21511046 [TBL] [Abstract][Full Text] [Related]
38. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. Segreti J; Jones RN; Bertino JS J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341 [TBL] [Abstract][Full Text] [Related]